DISCLOSURES: Dr. Partridge has received honoraria for serving as a consultant to AstraZeneca and Novartis. No other conflicts of interest relevant to this article were reported.
Patient adherence and persistence with oral anticancer treatment†
Article first published online: 16 JAN 2009
Copyright © 2009 American Cancer Society, Inc.
CA: A Cancer Journal for Clinicians
Volume 59, Issue 1, pages 56–66, January/February 2009
How to Cite
Ruddy, K., Mayer, E. and Partridge, A. (2009), Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians, 59: 56–66. doi: 10.3322/caac.20004
- Issue published online: 19 JAN 2009
- Article first published online: 16 JAN 2009
Given the recent significant increase in the use of oral therapies in cancer management, an understanding of patients' adherence to and persistence with oral therapy is crucial. Nonadherence and early cessation may be substantial barriers to the delivery of valuable therapies, and may impair health. Potential obstacles to adherence and persistence include personal characteristics, treatment features, and system factors. Techniques for measuring adherence and persistence include self-report, pill counts, microelectronic monitoring systems (MEMS), prescription database analysis, and the assessment of serum or urine drug levels. This review article describes available data regarding adherence and persistence among patients with cancer, as well as studies of interventions to improve adherence. All reports of studies of adherence with oral cancer therapy that the authors could find on PubMed or in the reference sections of these PubMed-located articles were included. Adherence and persistence rates ranged from 16% to 100% with different therapies and different methods of measurement. Studies that included educational, behavioral, and multidimensional interventions to improve adherence were also described. CA Cancer J Clin 2009;59:56–66. © 2009 American Cancer Society.